We have located links that may give you full text access.
CLINICAL TRIAL
COMPARATIVE STUDY
JOURNAL ARTICLE
Comparison of the efficacy of two vaginal progesterone formulations, Crinone 8% gel and Utrogestan capsules, used for luteal support in blastocyst stage embryo transfers.
Taiwanese Journal of Obstetrics & Gynecology 2009 December
OBJECTIVE: To compare the efficacy of two vaginal progesterone formulations, Crinone gel and Utrogestan capsules, for luteal phase support in blastocyst stage embryo transfers.
MATERIALS AND METHODS: We analyzed 460 consecutive cycles in patients undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI)-blastocyst transfer (BT) treatment at our institution between January 2004 and December 2007. Patients applied either Crinone 8% vaginal gel (90 mg, once daily) or Utrogestan vaginal capsules (200 mg, four times daily) for luteal supplementation. Progesterone was administered from the day of oocyte retrieval to pregnancy confirmation. Clinical pregnancy and implantation rates were the main outcome measures.
RESULTS: The clinical pregnancy rate (58.7% vs. 44.3%) and implantation rate (32.04% vs. 23.89%) were significantly higher in the Crinone group compared with the Utrogestan group after IVF/ICSI-BT treatment.
CONCLUSION: Luteal phase support with Crinone 8% vaginal gel (90 mg daily) resulted in better clinical pregnancy and implantation rates than Utrogestan vaginal capsules (200 mg, four times daily) in IVF/ICSI-BT cycles.
MATERIALS AND METHODS: We analyzed 460 consecutive cycles in patients undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI)-blastocyst transfer (BT) treatment at our institution between January 2004 and December 2007. Patients applied either Crinone 8% vaginal gel (90 mg, once daily) or Utrogestan vaginal capsules (200 mg, four times daily) for luteal supplementation. Progesterone was administered from the day of oocyte retrieval to pregnancy confirmation. Clinical pregnancy and implantation rates were the main outcome measures.
RESULTS: The clinical pregnancy rate (58.7% vs. 44.3%) and implantation rate (32.04% vs. 23.89%) were significantly higher in the Crinone group compared with the Utrogestan group after IVF/ICSI-BT treatment.
CONCLUSION: Luteal phase support with Crinone 8% vaginal gel (90 mg daily) resulted in better clinical pregnancy and implantation rates than Utrogestan vaginal capsules (200 mg, four times daily) in IVF/ICSI-BT cycles.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app